CARGO Therapeutics, Inc. (NASDAQ:CRGX) Shares Acquired by Barclays PLC

Barclays PLC boosted its holdings in CARGO Therapeutics, Inc. (NASDAQ:CRGX) by 226.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 56,354 shares of the company’s stock after purchasing an additional 39,102 shares during the quarter. Barclays PLC owned approximately 0.12% of CARGO Therapeutics worth $1,039,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently added to or reduced their stakes in the business. Geode Capital Management LLC increased its stake in shares of CARGO Therapeutics by 80.6% during the 3rd quarter. Geode Capital Management LLC now owns 838,279 shares of the company’s stock valued at $15,469,000 after acquiring an additional 374,018 shares during the last quarter. Wellington Management Group LLP increased its position in CARGO Therapeutics by 4.1% during the third quarter. Wellington Management Group LLP now owns 2,042,723 shares of the company’s stock worth $37,688,000 after purchasing an additional 79,782 shares during the last quarter. Sphera Funds Management LTD. raised its stake in CARGO Therapeutics by 22.5% during the third quarter. Sphera Funds Management LTD. now owns 190,506 shares of the company’s stock worth $3,515,000 after purchasing an additional 35,000 shares during the period. State Street Corp boosted its holdings in shares of CARGO Therapeutics by 11.7% in the 3rd quarter. State Street Corp now owns 839,861 shares of the company’s stock valued at $15,495,000 after purchasing an additional 88,000 shares during the last quarter. Finally, RTW Investments LP boosted its holdings in shares of CARGO Therapeutics by 0.5% in the 3rd quarter. RTW Investments LP now owns 4,098,955 shares of the company’s stock valued at $75,626,000 after purchasing an additional 20,833 shares during the last quarter. 93.16% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

CRGX has been the topic of several research reports. William Blair started coverage on CARGO Therapeutics in a research report on Tuesday, November 26th. They issued an “outperform” rating on the stock. Chardan Capital reaffirmed a “buy” rating and issued a $28.00 price objective on shares of CARGO Therapeutics in a research note on Wednesday, November 13th. Finally, HC Wainwright reissued a “buy” rating and set a $33.00 target price on shares of CARGO Therapeutics in a research report on Friday, November 15th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, CARGO Therapeutics has an average rating of “Buy” and a consensus price target of $31.80.

CARGO Therapeutics Stock Down 7.1 %

Shares of NASDAQ CRGX opened at $11.18 on Wednesday. CARGO Therapeutics, Inc. has a 1-year low of $10.91 and a 1-year high of $33.92. The business has a 50-day moving average of $16.10 and a 200-day moving average of $17.69.

CARGO Therapeutics (NASDAQ:CRGX) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.88) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.14) by $0.26. Analysts anticipate that CARGO Therapeutics, Inc. will post -3.73 EPS for the current fiscal year.

CARGO Therapeutics Profile

CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.